Munich Re's December 11, 2025 Investor Day put the portfolio arithmetic on the record: L&H reinsurance, Global Specialty Insurance, and ERGO rise from roughly 50% of group earnings to roughly 60% by 2030. The corollary, stated less prominently, is that P&C reinsurance falls from about half of group net results to about 40%.

Read as capacity withdrawal, that is wrong. The 2026 guidance and the retrocession decisions point the other way.

~50%
P&C reinsurance share of Munich Re group net results in 2025 (€3.308B of €6.121B)
~40%
Targeted P&C reinsurance share of group net results by 2030 under Ambition 2030
>18%
Group return on equity target by end of 2030, up from approximately 14% in 2025

Key Takeaways

  • P&C reinsurance contributed €3.308 billion of the €6.121 billion 2025 group net result, a 54% share, against a 40% target for 2030.
  • The three other pillars go from 46% to 60% collectively, a 14-point shift over five years, or roughly 3 points of relative rebalancing a year.
  • Retrocession fell from roughly $1.55 billion to approximately $600 million for 2026, with the Eden Re and Leo Re sidecars discontinued and the Queen Street cat bond not renewed.
  • Q1 2026 printed a 66.8% reported combined ratio against 80.3% normalized, on major losses of €108 million versus a quarterly budget near €450 million.
  • GSI targets a combined ratio of 87-90% by 2030 from the 90% guided for 2026, a 0 to 3 point improvement across four years.

The 2025 Baseline the Target Shifts

The starting mix is what makes the 40% figure legible.

Munich Re's 2025 net result of €6.121 billion beat the €6.0 billion target and marked a fifth consecutive year of guidance outperformance. P&C reinsurance contributed €3.308 billion, up from €3.153 billion in 2024, on a 73.5% combined ratio improved from 77.3%. L&H reinsurance contributed €1.334 billion, down from €1.545 billion, on a technical result of €1.715 billion that cleared its €1.7 billion target. ERGO contributed €917 million against €900 million guidance on insurance revenue of €21.681 billion. Global Specialty Insurance contributed €562 million, up sharply from €182 million after a loss-heavy prior period in marine, aviation, and specialty.

On net result that is P&C reinsurance at 54%, L&H at 22%, ERGO at 15%, and GSI at 9%. Ambition 2030 asks the last three to move collectively from 46% to 60%, which is 14 points across five years, or roughly 3 points of relative rebalancing a year.

Each of the three growth mandates has its own shape. L&H technical result is guided from €1.7 billion to €2.4-2.7 billion by 2030, an 8-12% CAGR, on biometric risk, longevity annuity reinsurance built off the UK pension risk transfer market and extended into continental Europe, Canada, and Australia, and capital relief solutions for cedants. GSI targets insurance revenue of €12-14 billion at a 5-9% CAGR. ERGO targets an 86-88% combined ratio by 2030 from the 89% guided for 2026.

Relative Share, Not Absolute Capacity

The arithmetic that resolves the misreading is short, and it changes what a cedant should expect at renewal.

Take the 2025 P&C reinsurance net result of €3.308 billion growing at low single digits. By 2030 that is roughly €3.5-3.7 billion. Against a group result growing toward the 18% ROE target from a €6.121 billion base, €3.5-3.7 billion lands at approximately 38-42% of the total. The 40% target arrives with no reduction in absolute underwriting capacity, purely because the other three pillars grow faster.

The 2026 guidance says the same thing directly: €5.4 billion of net profit from the combined reinsurance segment, with P&C reinsurance targeted at an 80% combined ratio on flat to modestly growing premium volume.

The retrocession decisions are the sharper evidence. Munich Re cut retrocession from roughly $1.55 billion to approximately $600 million for 2026, discontinued the Eden Re and Leo Re sidecars and let the Queen Street cat bond lapse. A reinsurer planning to shrink its P&C book does not simultaneously stop ceding it. That is a company retaining more of a portfolio it believes is well priced rather than paying away margin to external capital whose cost has risen against its own.

For a cedant the operative consequence is the reservation price. Without retrocession cushioning the net position, Munich Re carries the full underwriting risk of each treaty, which strengthens rather than weakens the case for holding rate. Its price at a renewal is set by what the 80% normalized combined ratio requires, not by what second and third-tier reinsurers will accept to fill capacity.

Q1 2026 shows why the normalized figure is the one to anchor to. The reported combined ratio was 66.8%, well inside the 80% target and far better than 83.9% in Q1 2025. Normalized, it was 80.3%. The difference is almost entirely major-loss experience: €108 million against a quarterly budget near €450 million, drawn from a 14% annual major-loss budget of roughly €1.8 billion, where Q1 2025 carried more than €1 billion on the Los Angeles wildfires. A cedant modeling available cushion off 66.8% is reading a benign quarter as structural headroom that the 80.3% says is not there.

The Diversification Is Bought in Books the Group Knows Least

The plan trades cycle exposure for execution risk, and the execution risk sits in the segments carrying the steepest growth mandates.

GSI's North American Excess and Surplus expansion is the clearest case. Swiss Re's sigma 02/2026 argues the E&S growth cycle is decelerating as admitted markets reassert across commercial lines where profitability has recovered. Munich Re is entering as that tailwind moderates, which leaves the residual niche: risks the admitted market will not take back regardless of cycle, including wildfire-exposed commercial property and large-limit excess casualty in social inflation jurisdictions. That is a materially narrower addressable market than headline E&S figures imply, and it means GSI pricing has to anchor to class-specific loss development rather than to market rate trends.

The margin path confirms the strategy is growth-led. A move from the 90% guided for 2026 to 87-90% by 2030 is a 0 to 3 point improvement over four years, modest against a softening market. That is revenue growth alongside margin rather than margin expansion, and it carries adverse selection exposure in the early portfolio years, before underwriting data in continental European specialty markets and unfamiliar E&S classes is credible enough to price accurately. Selectivity governs the expansion, which is the right posture and an easier one to hold in a strategy presentation than in a competitive submission where Lloyd's syndicates and US specialty carriers are pricing to defend share.

ERGO's contribution rests on a comparable bet. The 86-88% combined ratio target leans on expense ratio improvement, and the operational expression of that is eliminating 1,000 positions over five years through AI-driven automation against a €600 million annual savings target. A five-year headcount program in a regulated German labor environment carries legal and productivity transition risk that a combined ratio target does not show.

So the group is buying earnings stability against P&C cycle volatility, which is a defensible enterprise-level trade against segments whose results swing far less than a cat-exposed treaty book. It is paying for it in three portfolios where its underwriting record is shortest, on a schedule that requires roughly 3 points of rebalancing every year for five years.

Further Reading

Sources